Roth Capital reiterated a Buy rating and $14.50 price target on Trevena (NASDAQ: TRVN) as the company announced that TRV130 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Trevena (TRVN) Trades Near Day's High; Up 60%September 1, 2015 10:48 AM Barclays Upgrades Trevena (TRVN) to OverweightSeptember 1, 2015 10:44 AM Pre-Open Stock Movers 09/01: (TRVN) (KTOS) (ALKS) Higher; (ADEP) (DLTR) (GPRO) Lower (more...)September 1, 2015 9:30 AM Needham & Company Reiterates Buy on Trevena (TRVN) Following Positive TRV130 Results September 1, 2015 8:45 AM Trevena (TRVN) PT Bumped to $14 at Cowen as TRV130 Shows Strong Safety And Efficacy ProfileSeptember 1, 2015 7:32 AM Trevena (TRVN) PT Raised to $20 at WedbushSeptember 1, 2015 6:44 AM After Hours Stocks Movers 08/31: (TRVN) (MTRX) (SUNE) Higher; (ADEP) Lower (more...)August 31, 2015 5:51 PM Trevena (TRVN) Announces TRV130 Phase 2b Met Primary Endpoint in Acute Postoperative PainAugust 31, 2015 4:02 PM Trevena Announces Positive Results from Phase 2b Study of TRV130 in Acute Postoperative PainAugust 31, 2015 4:01 PM